Preclinical Toxicity Study and Tissue Distribution of YSCH- 01 Injection via Intratumoral Injection, Intravenous Injection, and Intraperitoneal Injection in Syrian Hamsters.

Ruoyu Chen, Xian-Long Fang, Hafiz Khuram Raza

Abstract read

In one paragraph

Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ruoyu Chen *Department of Clinical Transformation, Shanghai Yuansong Biotechnology Company Limited, Shanghai, 201499, China.

Xian-Long Fang *Department of Clinical Transformation, Shanghai Yuansong Biotechnology Company Limited, Shanghai, 201499, China.

Hafiz Khuram RazaDepartment of Clinical Transformation, Shanghai Yuansong Biotechnology Company Limited, Shanghai, 201499, China. hafizkhuram.raza@hotmail.com.

Funding

Academician Expert Workstation Grants 20R9004076411Shanghai science and technology support project on biomedicine in the action plan of Science and Technology Innovation 19431904200

6 · The paper itself

Abstract

backgroundRecombinant L-IFN Adenovirus (YSCH-01) is a modified oncolytic adenovirus, which showed good curative effects in a variety of solid tumors. The safety of YSCH-01 needs to be evaluated for non-clinical research.

methodsThis toxicity and distribution study of YSCH-01 injection via ITU/IV/IP injection in Syrian Hamster was conducted to prepare an investigational new drug (IND) application. The endpoints included mortality/moribundity, clinical observation, body weight, palpable mass examination, food consumption, ophthalmology, and clinical pathology. Toxicokinetics, ADA test, viral shedding, and tissue bio-distribution were analyzed.

resultsThe severely toxic dose in 10% of animals was 1 × 10

conclusionsOur study demonstrated the toxicity and potential toxicity of YSCH-01 in Syrian hamsters and evaluated its tissue distribution in hamsters after a single administration. STD10 results in hamsters support the safety of the estimated dosage for future clinical studies.

Indexed as

AdenoviridaeOncolytic VirotherapyOncolytic VirusesAnimalsCricetinaeFemaleGenetic VectorsInjections, IntralesionalInjections, IntraperitonealInjections, IntravenousMaleMesocricetusRecombinant ProteinsTissue DistributionRecombinant Proteinsbio-distributionL-IFNoncolytic adenovirustoxicokineticsYSCH- 01

Identifiers

PMID40342022

DOI10.1007/s11095-025-03863-x

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.